Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American Academy of Ophthalmology Annual Meeting

DUBLIN, Oct. 19, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company with a nearly 70-year heritage in ophthalmology, will present new data at the Annual Meeting of the American College of Ophthalmology (AAO) to be held in Chicago, Illinois. The Retina Subspecialty Day (October 26-27) will feature two late-breaker presentations on the company's ophthalmology pipeline, including new findings for abicipar in patients with neovascular age-related macular degeneration (nAMD) and brimonidine drug delivery system (DDS) in patients with geographic atrophy secondary to AMD. Additional company-sponsored data will also be presented during the AAO poster sessions.

"The data demonstrate our continued dedication to research and innovation aimed at finding new solutions to a cross-section of eye diseases," said David Nicholson, Chief Research & Development Officer at Allergan. "At AAO, we look forward to presenting results from studies that have the potential to define new treatment approaches as well as continue to improve upon current patient care."

Allergan will present five abstracts, including two podium and three poster presentations (all noted in local Central Daylight Time):

Retina Subspecialty Day – Section XI: First-time Results of Clinical Trials (Friday, October 26, 5:08-5:36 PM):

• Safety and Efficacy of Abicipar in Patients with Neovascular Age‐related Macular Degeneration
• Author: Khurana R.
• Time: 5:15-5:22 PM
  
  
• Brimonidine DDS Safety and Efficacy in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
• Author: Freeman W et al
• Time: 5:29-5:36 PM

AAO Poster Session One (Saturday, October 27 - Sunday, October 28)
* Authors present Sunday, Oct. 28th, 12:45-1:45 PM):

• Symptom Relief in Dry Eye Subjects Following Intranasal Tear Neurostimulation
• Authors: Jerkins G et al.
  
  
• Real World Neovascular Age-related Macular Degeneration Treatment and Outcomes: Analyses of US Electronic Health Records
• Authors: Kiss S et al. 
  
  
• Real-World Efficacy of Selective Laser Trabeculoplasty in the UK and Factors Predicting Success
  *Additional presentation in the Poster Theater, Sunday, Oct. 28^th, 3:30-4:30 PM
• Authors: Khawaja A et al.

ALLERGAN ANALYST CONFERENCE CALL AND WEBCAST

Allergan will host an Analyst Event at the 2018 AAO Annual Meeting including a conference call and webcast on Friday, October 26, at 6:30 p.m. Central Time (7:30 p.m. Eastern Time). The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 1974409.

A replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 10:30 p.m. Eastern Time on November 26, 2018. The replay may be accessed by dialing (855) 859-2056 or (404) 537-3406 and entering the conference ID 1974409.

To access the webcast, please visit Allergan's Investor Relations website at https://www.allergan.com/investors/events-presentations. A replay of the webcast will also be available on Allergan's Investor Relations website.

About Allergan Eye Care

As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry over the last 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion. Our eye care pipeline includes 13 additional agents for multiple ocular conditions.

Our commitment to the well-being of patients is also reflected in philanthropy. Allergan and The Allergan Foundation support more than 150 organizations around the world working to improve lives and communities. We remain steadfast in helping eye care providers deliver the best in patient care through innovative products and outreach programs.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Allergan:
Investors:
Daphne Karydas
(862) 261-8006

Karina Calzadilla
(862) 261-7328

Media:
Amy Rose
(862) 261-7001

Fran DeSena
(862) 261-8820

SOURCE Allergan plc

Related Links

www.allergan.com